Market news

Phase 3 EU trial protocols flag potential liver safety risks for Bristol Myers Squibb’s admilparant in pulmonary fibrosis—see what it means for BMY.

Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

On September 25, Bristol-Myers Squibb Company (NYSE:BMY) announced milestone results from its Phase 3 EXCALIBER-RRMM trial evaluating Zenbexus in combination with daratumumab and dexamethasone (ZDd) for relapsed or refractory multiple myeloma. At a median follow-up of 15.7 months across 420 patients, ZDd demonstrated a statistically significant improvement in minimal residual disease (MRD)-negative complete response rates […]

On September 8, Bristol-Myers Squibb Company (NYSE:BMY) announced positive Phase 2 results from its registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel (arlo-cel) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful overall response rate (ORR) alongside strong complete response rates […]

Originally published by the Bristol Myers Squibb FoundationNORTHAMPTON, MA / ACCESS Newswire / September 28, 2026 / Francis Kwoba is a 68-year-old retired policeman from Bungoma County, Kenya. During one of his usual morning runs, he experienced a sudden sharp pain in his chest.

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

Bristol-Myers Squibb (NYSE:BMY) has picked Onco360 to join the restricted specialty pharmacy network for ZENBEXUS (iberdomide). ZENBEXUS, a newly approved therapy for certain multiple myeloma patients, will be dispensed through a Risk Evaluation and Mitigation Strategy program. Onco360 will handle specialty dispensing and clinical support for eligible patients as ZENBEXUS enters commercial rollout for an underserved group. The selection of Onco360 for ZENBEXUS distribution comes against...

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

The Rare Access Action Project (RAAP) announced today that Bristol Myers Squibb (BMS) has joined RAAP as its newest member, expanding the coalition of patient and life sciences stakeholders working together to address access and coverage challenges affecting people living with rare diseases.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.

PRINCETON, N.J., September 18, 2026--Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

Ultragenyx’s second gene therapy approval since August gives it another sellable voucher. Elsewhere, Roche declared success in a blood cancer trial and a cell therapy maker is cutting costs.

Bristol Myers Squibb (BMY) closed the most recent trading day at $62.84, moving 1.19% from the previous trading session.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

PRINCETON, N.J., September 16, 2026--Bristol Myers Squibb Announces Dividend

Collecting $10,000 a year from Bristol Myers Squibb sounds straightforward until you factor in a looming patent cliff that threatens the very earnings funding that payout. Here is what the math and the risk actually look like together.

Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met the main goal of a mid-stage trial in patients with advanced multiple myeloma who had already gone through four major classes of standard treatments. The therapy produced a statistically significant and clinically meaningful improvement in overall response rates. It also met […]

Bristol Myers Squibb (BMY) reached $63.75 at the closing of the latest trading day, reflecting a -1.02% change compared to its last close.

The pharmaceutical sector was hit with major pipeline news on September 1 when Novartis AG (NYSE:NVS) paused eight clinical trials of rap-cel, its experimental CAR-T cell therapy targeting autoimmune and neurological disorders. The suspension, effective August 24, followed three patient deaths caused by severe, life-threatening immune reactions (immune effector cell-associated hemophagocytic syndrome). Novartis is currently […]

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

Bristol Myers Squibb's aggressive M&A and in-house R&D efforts have driven the portfolio renewal cadence and ongoing valuation re-rating. Click for more on BMY.

In the most recent trading session, Bristol Myers Squibb (BMY) closed at $66.82, indicating a -1.87% shift from the previous trading day.